The UK’s Joint Committee on Vaccination and Immunisation (JCVI) has published recommendations on reducing the rates of Gonorrhoea and Mpox in the population.
They propose a routine but targeted vaccination programme for the prevention of gonorrhoea, alongside a routine vaccination programme against mpox for those at highest risk.
It is suggested both programmes be offered on an ‘opportunistic basis’ – through specialist sexual health services which have the experience in assessment and identification of those who are at increased risk of infection with bacterial sexually transmitted infections. While this would primarily target gay and bisexual men and other men who have sex with men, others deemed at risk should also be offered vaccination.
The recommendations note that even with the modest vaccine documented effectiveness against gonorrhoea (between 32.7% to 42%) many cases of gonorrhoea could be prevented. The disease itself doesn’t protect from reinfection and affected individuals are commonly reinfected. While the main benefit of a vaccination programme is expected to be at a community level with a significant reduction in the number of cases overall, vaccinated individuals could expect to have some reduction in their own risk of contracting gonorrhoea.
Professor Andrew Pollard, Chair of the JCVI, said:
“Introducing a MenB vaccination programme to prevent gonorrhoea in England would be a world first and should significantly help to reduce levels of gonorrhoea, which are currently at a record high.”
While Mpox cases were limited thanks to rapid action on the recent UK outbreak, recorded cases of gonorrhoea saw a rapid rise last year. With gonorrhoea becoming increasingly resistant to antibiotics, tackling this infection is a serious health concern.
Department of Health and Social Care ministers will consider the proposals but they may not be implemented.
